ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
이파타설팁 시장 규모는 최근 급속도로 확대되고 있습니다. 2024년 7억 6,000만 달러에서 2025년에는 8억 6,000만 달러에 달하고, CAGR 13.6%로 성장할 전망입니다. 실적기간 내 성장은 세계적인 암 이환율의 상승, 전립선암의 유병률 증가, 임상시험 수 증가, 암 연구개발에의 자금 투자 증가, 맞춤 의료에의 기호의 고조에 기인하고 있습니다.
이파타설팁 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 13.2%로 14억 2,000만 달러로 성장할 전망입니다. 예측기간에 있어서 성장의 원동력은 정부 지원책의 채용 증가, 면역조절치료에 대한 수요 증가, 정밀의료에 대한 주목의 확대, 헬스케어 서비스에 대한 투자의 확대, 의료비 증가입니다. 예측기간의 주요 동향에는 표적요법의 발전, 생명공학 및 제약 연구의 진전, 계산생물학 기술의 통합, 이파타설팁의 새로운 치료 용도의 개발 등이 있습니다.
암의 유병률 증가는 향후 수년간 이파타설팁 시장의 확대를 촉진할 것으로 예측되고 있습니다. 암은 신체의 비정상적인 세포의 통제 불가능한 증식과 확산을 특징으로 하는 질환군을 포함합니다. 이러한 암 사례 증가는 건강에 해로운 식생활, 흡연, 운동 부족, 과도한 알코올 사용과 같은 라이프 스타일 요인과 관련이 있습니다. 이파타설팁은 PI3K/ACT 신호전달 경로를 표적으로 함으로써 암 치료를 지원하고 종양 성장과 세포 증식을 효과적으로 지연시킵니다. 암세포의 생존율과 치료 저항성을 저하시켜 치료 성적과 예후 개선으로 이어집니다. 예를 들어, 2024년 10월 영국의 국민보건서비스(National Health Service)는 신규 암 진단이 5% 증가하여 2021년 329,664례에서 2022년에는 346,217례에 이르렀으며, 하루 평균 948례가 새롭게 암으로 진단된다고 보고했습니다. 이와 같이 암 유병률 증가가 이파타설팁 시장의 성장을 뒷받침하고 있습니다.
맞춤 의료에 대한 선호도 증가는 향후 이파타설팁 시장의 성장을 뒷받침할 것으로 예측됩니다. 맞춤 의료는 개인 고유의 유전자 프로파일, 라이프스타일, 환경에 기초하여 치료 및 예방을 조절하는 것을 말합니다. 유전체학의 진보는 유전적 돌연변이의 정확한 식별과 맞춤형 치료를 가능하게 함으로써 맞춤 의료의 채용을 촉진하고 있습니다. 이파타설팁은 PI3K/ACT 신호전달 경로를 표적으로 함으로써 맞춤 의료에 공헌하고, 개별 종양의 유전적 특징에 따른 암 치료를 가능하게 합니다. 특정 유전적, 분자적 특징에 대처함으로써 치료 효과를 높여, 치료 저항성을 저하시키고, 환자의 결과를 개선합니다. 예를 들어, 2024년 2월 맞춤의료연합(Personalized Medicine Coalition)은 미국 식품의약국이 2023년에 26개의 새로운 개인화 의약품을 승인했으며 이는 2022년 12개에서 증가했다고 보고했습니다. 따라서 맞춤 의료의 채용이 증가하고 있는 것이 이파타설팁 시장의 성장을 지지하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 이파타설팁 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 이파타설팁 시장 : 성장률 분석
세계의 이파타설팁 시장 실적 : 규모와 성장(2019-2024년)
세계의 이파타설팁 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 이파타설팁 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 이파타설팁 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
전립선암
유방암
기타 암
세계의 이파타설팁 시장 : 제형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
태블릿
캡슐
기타 제형
세계의 이파타설팁 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
정맥내 투여
세계의 이파타설팁 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 이파타설팁 시장 세분화 : 전립선암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
전이성 거세저항성 전립선암(mCRPC)
전이성 호르몬 감수성 전립선암(mHSPC)
비전이성 전립선암
세계의 이파타설팁 시장 세분화 : 유방암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
삼중음성 유방암(TNBC)
호르몬 수용체 양성 또는 인간 상피 성장인자 수용체 2(HER2) 음성 유방암
인간 상피 성장인자 수용체 2(HER2) 양성 유방암
세계의 이파타설팁 시장 세분화 : 기타 암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
난소암
위암
췌장암
대장암
폐암
제7장 지역별/국가별 분석
세계의 이파타설팁 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 이파타설팁 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
이파타설팁 시장 : 경쟁 구도
이파타설팁 시장 : 기업 프로파일
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Abcam plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Cayman Chemical Company Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Selleck Chemicals LLC : 개요, 제품 및 서비스, 전략 및 재무 분석
ChemScene LLC : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Creative Biolabs Inc.
TargetMol Chemicals Inc.
MedChemExpress LLC
BOC Sciences Inc.
Adooq Bioscience LLC
Axon Medchem BV
MedKoo Biosciences Inc.
Ambeed Inc.
InvivoChem LLC
Focus Biomolecules Inc.
ApexBio Technology LLC
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
이파타설팁 시장(2029년) : 새로운 기회를 제공하는 국가
이파타설팁 시장(2029년) : 새로운 기회를 제공하는 부문
이파타설팁 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Ipatasertib is an oral, small-molecule inhibitor that selectively targets protein kinase B (AKT), a critical protein in the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, which is often overactive in cancer cells. By inhibiting AKT, it disrupts cancer cell growth, survival, and proliferation, helping to slow disease progression and improve the efficacy of other therapies.
The primary indications of ipatasertib are prostate cancer, breast cancer, and other cancers. Prostate cancer develops in the prostate, a small gland in men responsible for producing seminal fluid. Ipatasertib is available in various dosage forms, including tablets and capsules, and is administered orally or intravenously. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The ipatasertib market research report is one of a series of new reports from The Business Research Company that provides ipatasertib market statistics, including the ipatasertib industry global market size, regional shares, competitors with the ipatasertib market share, detailed ipatasertib market segments, market trends, and opportunities, and any further data you may need to thrive in the ipatasertib industry. This ipatasertib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The ipatasertib market size has grown rapidly in recent years. It will grow from $0.76 billion in 2024 to $0.86 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period is attributed to the rising incidence of cancer globally, increasing prevalence of prostate cancer, growing number of clinical trials, higher funding for cancer research and development, and greater preference for personalized medicine.
The ipatasertib market size is expected to see rapid growth in the next few years. It will grow to $1.42 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period is driven by increasing adoption of supportive government initiatives, rising demand for immunomodulatory treatments, expanding focus on precision medicine, growing investment in healthcare services, and higher healthcare expenditure. Key trends in the forecast period include advancements in targeted therapies, progress in biotechnology and pharmaceutical research, integration of computational biology technologies, and development of new therapeutic applications for ipatasertib.
The growing prevalence of cancer is anticipated to drive the expansion of the ipatasertib market in the coming years. Cancer encompasses a group of diseases marked by uncontrolled growth and spread of abnormal cells within the body. This rise in cancer cases is linked to lifestyle factors such as unhealthy diets, smoking, lack of physical activity, and excessive alcohol use. Ipatasertib supports cancer treatment by targeting the PI3K/AKT signaling pathway, effectively slowing tumor growth and cell proliferation. It helps reduce cancer cell survival and therapy resistance, leading to better treatment outcomes and prognosis. For example, in October 2024, the National Health Service in the UK reported a 5% increase in new cancer diagnoses, rising from 329,664 cases in 2021 to 346,217 in 2022, averaging 948 new cases daily. Thus, the increasing prevalence of cancer is fueling the growth of the ipatasertib market.
The increasing preference for personalized medicine is expected to boost the growth of the ipatasertib market going forward. Personalized medicine involves tailoring treatment and prevention based on an individual's unique genetic profile, lifestyle, and environment. Advancements in genomics have driven the adoption of personalized medicine by enabling accurate identification of genetic variations and customized treatments. Ipatasertib contributes to personalized medicine by targeting the PI3K/AKT signaling pathway, allowing cancer therapies to be tailored according to individual tumor genetics. It enhances treatment efficacy by addressing specific genetic and molecular traits, lowering resistance to treatment and improving patient outcomes. For instance, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, up from 12 in 2022. Therefore, the rising adoption of personalized medicine is supporting the growth of the ipatasertib market.
The increase in healthcare spending is expected to support the growth of the ipatasertib market in the future. Healthcare expenditure includes all financial resources spent on medical services, treatments, infrastructure, research, and public health efforts to improve health outcomes. The demand for higher healthcare spending is driven by the rising prevalence of chronic illnesses, which require prolonged and often costly care. Increased healthcare spending benefits ipatasertib development by providing more funds and resources for research and clinical trials, facilitating progress in innovative cancer therapies. This investment helps speed up drug development and expands access to targeted treatments, enhancing patient care and treatment efficiency. For example, in May 2024, the UK's Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure in 2023, marking a 0.9% rise compared to 2022. Consequently, rising healthcare expenditure is propelling the growth of the ipatasertib market.
Major players in the ipatasertib market are F. Hoffmann-La Roche AG, Abcam plc, Cayman Chemical Company Inc., Selleck Chemicals LLC, ChemScene LLC, Creative Biolabs Inc., TargetMol Chemicals Inc., MedChemExpress LLC, BOC Sciences Inc., Adooq Bioscience LLC, Axon Medchem BV, MedKoo Biosciences Inc., Ambeed Inc., InvivoChem LLC, Focus Biomolecules Inc., and ApexBio Technology LLC.
North America was the largest region in the ipatasertib market in 2024. The regions covered in ipatasertib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ipatasertib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The ipatasertib market consists of sales of capivasertib (AZD5363), perifosine, afuresertib (GSK2110183), MK-2206, and taselisib (GDC-0032). Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ipatasertib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ipatasertib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ipatasertib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ipatasertib market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Indication: Prostate Cancer; Breast Cancer; Other Cancers
2) By Dosage Form: Tablets; Capsules; Other Dosages
3) By Route Of Administration: Oral; Intravenous
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Prostate Cancer: Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Non-Metastatic Prostate Cancer
2) By Breast Cancer: Triple-Negative Breast Cancer (TNBC); Hormone Receptor-Positive Or Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer; Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
3) By Other Cancers: Ovarian Cancer; Gastric Cancer; Pancreatic Cancer; Colorectal Cancer; Lung Cancer
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Ipatasertib Market Characteristics
3. Ipatasertib Market Trends And Strategies
4. Ipatasertib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Ipatasertib Growth Analysis And Strategic Analysis Framework
5.1. Global Ipatasertib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Ipatasertib Market Growth Rate Analysis
5.4. Global Ipatasertib Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Ipatasertib Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Ipatasertib Total Addressable Market (TAM)
6. Ipatasertib Market Segmentation
6.1. Global Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prostate Cancer
Breast Cancer
Other Cancers
6.2. Global Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Capsules
Other Dosages
6.3. Global Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
6.4. Global Ipatasertib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Ipatasertib Market, Sub-Segmentation Of Prostate Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Non-Metastatic Prostate Cancer
6.6. Global Ipatasertib Market, Sub-Segmentation Of Breast Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Triple-Negative Breast Cancer (TNBC)
Hormone Receptor-Positive Or Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
6.7. Global Ipatasertib Market, Sub-Segmentation Of Other Cancers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ovarian Cancer
Gastric Cancer
Pancreatic Cancer
Colorectal Cancer
Lung Cancer
7. Ipatasertib Market Regional And Country Analysis
7.1. Global Ipatasertib Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Ipatasertib Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Ipatasertib Market
8.1. Asia-Pacific Ipatasertib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Ipatasertib Market
9.1. China Ipatasertib Market Overview
9.2. China Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Ipatasertib Market
10.1. India Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Ipatasertib Market
11.1. Japan Ipatasertib Market Overview
11.2. Japan Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Ipatasertib Market
12.1. Australia Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Ipatasertib Market
13.1. Indonesia Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Ipatasertib Market
14.1. South Korea Ipatasertib Market Overview
14.2. South Korea Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Ipatasertib Market
15.1. Western Europe Ipatasertib Market Overview
15.2. Western Europe Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Ipatasertib Market
16.1. UK Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Ipatasertib Market
17.1. Germany Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Ipatasertib Market
18.1. France Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Ipatasertib Market
19.1. Italy Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Ipatasertib Market
20.1. Spain Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Ipatasertib Market
21.1. Eastern Europe Ipatasertib Market Overview
21.2. Eastern Europe Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Ipatasertib Market
22.1. Russia Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Ipatasertib Market
23.1. North America Ipatasertib Market Overview
23.2. North America Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Ipatasertib Market
24.1. USA Ipatasertib Market Overview
24.2. USA Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Ipatasertib Market
25.1. Canada Ipatasertib Market Overview
25.2. Canada Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Ipatasertib Market
26.1. South America Ipatasertib Market Overview
26.2. South America Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Ipatasertib Market
27.1. Brazil Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Ipatasertib Market
28.1. Middle East Ipatasertib Market Overview
28.2. Middle East Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Ipatasertib Market
29.1. Africa Ipatasertib Market Overview
29.2. Africa Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Ipatasertib Market Competitive Landscape And Company Profiles
30.1. Ipatasertib Market Competitive Landscape
30.2. Ipatasertib Market Company Profiles
30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Abcam plc Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Cayman Chemical Company Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Selleck Chemicals LLC Overview, Products and Services, Strategy and Financial Analysis
30.2.5. ChemScene LLC Overview, Products and Services, Strategy and Financial Analysis
31. Ipatasertib Market Other Major And Innovative Companies
31.1. Creative Biolabs Inc.
31.2. TargetMol Chemicals Inc.
31.3. MedChemExpress LLC
31.4. BOC Sciences Inc.
31.5. Adooq Bioscience LLC
31.6. Axon Medchem BV
31.7. MedKoo Biosciences Inc.
31.8. Ambeed Inc.
31.9. InvivoChem LLC
31.10. Focus Biomolecules Inc.
31.11. ApexBio Technology LLC
31.12. 0
31.13. 0
31.14. 0
31.15. 0
32. Global Ipatasertib Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Ipatasertib Market
34. Recent Developments In The Ipatasertib Market
35. Ipatasertib Market High Potential Countries, Segments and Strategies
35.1 Ipatasertib Market In 2029 - Countries Offering Most New Opportunities
35.2 Ipatasertib Market In 2029 - Segments Offering Most New Opportunities
35.3 Ipatasertib Market In 2029 - Growth Strategies
